Are longevity clinics actually worth the money?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Longevity clinics are usually not worth the money for healthy, average-risk adults, but they can be valuable when they deliver unusually good preventive care, coordination and follow-up.
The industry sells three different products under one label: better primary care, aggressive screening and experimental anti-aging medicine. The first can be genuinely useful; the other two need much more skepticism.
The strongest part of a good clinic is rarely the futuristic technology. It is the extra physician time, organized records, rapid access and persistence needed to turn known risks such as high blood pressure, harmful cholesterol, poor fitness or sleep apnea into actual treatment.
More testing does not automatically mean more prevention. Very large laboratory panels and whole-body scans almost guarantee abnormalities, many of which lead to repeat imaging, specialist visits or surveillance without improving health.
The economics are lopsided. Moving from a few hundred dollars to $15,000 buys much more convenience and diagnostic coverage, but the expected medical benefit does not rise in proportion to the price.
Some advanced tests are useful when risk is already elevated. Genetics, targeted imaging, sleep studies, DEXA and cardiovascular testing become more defensible when family history, age, symptoms or an unresolved treatment decision gives the result a clear purpose.
The most marketable technologies often have the weakest evidence. Biological age scores, glucose monitoring in healthy users, NAD+ infusions, peptide stacks and off-label longevity drugs can generate data or biological stories without proving that customers live longer or avoid major disease.
Whole-body MRI and multi-cancer blood testing may occasionally find serious disease, but detection is not the same as benefit. The missing numbers are how often screening triggers follow-up, how often that follow-up finds nothing important and whether mortality eventually falls.
The people most likely to benefit are those with neglected care, strong inherited risk or several connected health problems that ordinary healthcare has managed badly. A healthy person with good primary care, appropriate screening and consistent exercise has much less room to gain.
The clearest sign of a high-quality clinic is restraint. A clinic that sometimes recommends fewer tests, explains false alarms and avoids reflexive prescribing is more credible than one competing on biomarker counts.
For most people, the best longevity strategy remains excellent primary care, evidence-based screening, fitness, sleep and sustained risk-factor treatment. A clinic becomes worth paying for only when it makes that basic system work materially better.
What are longevity clinics really selling?
Longevity clinics currently sell a mix of excellent preventive care, aggressive screening and experimental anti-aging medicine, and those three things do not deserve the same price or trust.
The cheaper end looks like upgraded laboratory access. Function Health now charges $365 a year for more than 160 tests, clinician review and an action plan. At the luxury end, Biograph charges $7,500 for its Core program and $15,000 for Black, which adds coronary CT angiography, lung CT, a multi-cancer blood test, sleep testing and continuous glucose monitoring. Human Longevity starts at $8,000 for whole-body MRI, whole-genome sequencing, cardiac imaging and more than 120 biomarkers.
Some clinics mainly fix problems that ordinary healthcare handles badly: rushed visits, scattered records, missed screening and weak follow-up. Others make their package feel more valuable by adding every test they can fit into one day. A third group goes further with biological age scores, NAD+ infusions, peptides, hormones or off-label drugs.
We need to keep those products separate before judging the price. A physician who finds uncontrolled blood pressure and keeps working with the patient until it improves is providing real preventive medicine. A clinic that gives a healthy person 30 normal scans, eight flagged biomarkers and an expensive supplement plan is selling a very different product.
| Current offer | Advertised price | What is included | What the buyer is mainly paying for |
|---|---|---|---|
| Function Health | $365 a year | 160+ laboratory tests, clinician review and an action plan | Broad, convenient blood testing |
| Biograph Core | $7,500 first year | Whole-body MRI, blood testing, DEXA, VO2 max and physician review | A premium diagnostic baseline |
| Human Longevity Executive Health | From $8,000 | Whole-body MRI, whole-genome sequencing, cardiac imaging and 120+ biomarkers | Integrated high-end screening |
| Biograph Black | $15,000 first year | Core testing plus cardiac CT, lung CT, multi-cancer testing, sleep testing and CGM | Maximum diagnostic coverage and follow-up |
If you want more recent data on this point, please see our latest longevity market report.
Why are so many people paying for longevity clinics now?
The longevity clinic boom is easy to understand: people can now buy advanced tests that used to sit inside research programs or specialist hospitals, while ordinary preventive care still feels fragmented and rushed.
Demand is no longer tiny. Function Health says its members have completed more than 50 million laboratory tests since 2023. Human Longevity says it has followed more than 10,000 clients. New clinics now compete on the number of biomarkers, scans and specialists they can place inside one visit.
The appeal goes beyond fear of aging. A customer gets several hours of attention, neatly organized results, rapid access to imaging and someone who explains the whole picture. Many people have never received that experience from their normal doctor. Wealthy clients also value the ability to complete weeks of appointments in one day.
The technology creates a second pull. Whole-body MRI, genome sequencing and multi-cancer blood tests sound as though they can reveal disease before normal medicine notices it. Buying them can therefore feel like responsible self-care.
Marketing then makes every outcome look like a win. A serious hidden disease becomes a powerful testimonial. A clean scan provides reassurance. A harmless abnormality that triggers three follow-up appointments receives far less attention. Customers see the dramatic discoveries more often than the false alarms, ambiguous findings and quiet cases where nothing useful changed.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Have longevity clinics proved they help people live longer?
No longevity clinic has proved that its complete program helps healthy customers live longer, and that missing evidence should shape every discussion about value.
The closest evidence we have comes from trials of general health checks. A JAMA review examined 19 randomized trials with follow-up lasting as long as 30 years. Health checks led to more diagnoses, more treatment of risk factors and better use of some preventive services. They did not consistently reduce deaths or cardiovascular events. Cochrane reached much the same conclusion across 15 trials: broad checks had little or no effect on total mortality, cancer mortality or deaths from ischemic heart disease.
Those older trials did not test the exact package clinics sell today. The scans and genomic tools are more advanced, but the standard of proof remains simple: do customers have fewer heart attacks, strokes, advanced cancers, fractures, disabilities or deaths? Finding more abnormalities is much easier.
A clinic may help an individual even before those long trials exist. It can discover untreated hypertension, severe sleep apnea, dangerous cholesterol or a cancer that would otherwise have appeared later. Yet a collection of striking cases cannot tell us how many healthy customers needed extra scans, biopsies or years of surveillance for every person helped.
Is the best part of a longevity clinic simply better primary care?
For many customers, the best part of a longevity clinic is ordinary preventive medicine delivered with more time, coordination and persistence than they usually receive.
The interventions most likely to extend healthy life are already familiar. Control high blood pressure. Treat harmful cholesterol when the risk justifies it. Stop smoking. Exercise. Maintain muscle and cardiorespiratory fitness. Vaccinate. Screen for cancers at the ages and risk levels where trials show a net benefit.
What often fails is execution. A rushed annual visit may identify a problem without making sure it gets fixed. A strong clinic can review the full history, find missing screening, coordinate specialists and follow the patient over several months. Good coaching also helps when it turns vague advice into scheduled training, realistic nutrition changes and measurable goals.
The danger appears when a fixed package replaces clinical judgment. An investigation of executive physicals at leading US hospitals found that many routinely offered electrocardiograms, exercise stress tests and other tests to asymptomatic clients. The US Preventive Services Task Force advises against screening low-risk adults with resting or exercise ECG because the expected harm can exceed the benefit.
A useful clinic starts with the person and then chooses the tests. A weaker one starts with an expensive menu and looks for reasons to use every item on it. The first approach can repair a real gap in healthcare. The second often produces more activity than health.
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Do 160 blood tests reveal hidden disease or just create more problems?
A 160-test panel will almost certainly produce flagged results, even in a healthy person, and many of those flags will have little medical importance.
Laboratory ranges usually capture about 95% of values in a reference population. A result can sit outside that range because of normal variation, recent exercise, hydration, a minor infection, menstrual timing, medication or the way the sample was handled. “Abnormal” does not automatically mean “disease.”
The arithmetic becomes uncomfortable as panels grow. Under a simplified model where 100 independent tests each place 95% of healthy people inside the reference range, the chance of at least one result falling outside is 99.4%. Real biomarkers are correlated, so the exact percentage will differ. The calculation still shows why a dashboard full of yellow and red markers is entirely expected.
Large panels can contain useful tests. ApoB may sharpen cardiovascular risk. Lipoprotein(a) is largely inherited and often worth measuring once. HbA1c can reveal diabetes or prediabetes. Thyroid, iron or vitamin testing can answer a real clinical question when symptoms or risk factors point that way.
The weak part is routine repetition of markers that have no clear treatment threshold or outcome evidence. Every extra measurement needs an answer to one practical question: what will we do differently if it is high or low? When the clinic cannot answer, the test is mostly producing content for the report.
| Number of independent tests | Chance all results stay within a 95% reference range | Chance at least one falls outside |
|---|---|---|
| 10 | 59.9% | 40.1% |
| 25 | 27.7% | 72.3% |
| 50 | 7.7% | 92.3% |
| 100 | 0.6% | 99.4% |
Is a full-body MRI worth thousands of dollars?
A full-body MRI is currently a poor routine purchase for a healthy, average-risk person, although it can make sense when family history, genetics or symptoms raise the odds of finding something serious.
A recent European Radiology meta-analysis combined 10 studies and 9,024 asymptomatic participants. Whole-body MRI found a confirmed cancer in about 1.6% of people. We would not dismiss that yield, but the review also found frequent incidental abnormalities, inconsistent scan protocols and no long-term evidence showing better survival or cost-effectiveness.
The American College of Radiology still finds insufficient evidence to recommend total-body MRI for people without symptoms, relevant risk factors or a strong family history. MRI avoids ionizing radiation. Most of the risk comes after the scan, when an uncertain finding needs to be investigated.
Human bodies contain cysts, nodules, benign tumors, old injuries and anatomical quirks. A scan may lead to contrast imaging, CT, ultrasound, specialist visits, biopsy or annual surveillance before anyone knows whether the finding mattered. Some cancers discovered through screening would never have harmed the patient, creating overdiagnosis.
A buyer should ask the clinic for three numbers: how often it finds a serious treatable condition, how often it recommends follow-up, and how often that follow-up ends with no important diagnosis. Clinics readily advertise the first number and rarely publish the full chain.
For someone carrying a high-risk cancer mutation, broad imaging can be part of specialist-led surveillance. For a low-risk customer buying reassurance, the scan can easily replace one uncertainty with several smaller ones.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Can a $949 blood test catch cancer early enough to matter?
The $949 Galleri test looks promising today, but the first large randomized trial did not prove enough benefit to make it routine screening for healthy longevity-clinic customers.
The NHS-Galleri trial enrolled more than 142,000 adults aged 50 to 77 and tested blood annually for three years. Its main goal was to reduce the combined number of stage III and stage IV cancers in a prespecified group of 12 cancers. The trial missed that endpoint.
There was an encouraging result underneath it. Stage IV diagnoses fell by about 14% across the three rounds, and the reduction became larger in later rounds. By the third round, stage IV cancers were down by more than a quarter. That pattern suggests repeated testing may move some diagnoses earlier.
We still do not know whether Galleri reduces cancer deaths. Screening can make survival from diagnosis look longer simply because the cancer was found sooner. It can also detect slower cancers that would never have become lethal. Mortality follow-up will settle more of the debate.
A positive result starts a diagnostic search. Galleri does not diagnose cancer or always locate it perfectly, so patients may need scans, scopes or biopsies. The company itself says the test has not been cleared or approved by the FDA and should be used alongside normal screening.
For an older person with elevated cancer risk who accepts the uncertainty, paying for Galleri can be a considered choice. Including it automatically in every premium package goes beyond the evidence we have now.
Will sequencing your whole genome actually change your care?
Whole-genome sequencing can uncover a serious inherited risk that changes care, but most healthy customers will not receive that kind of result.
The clearest evidence comes from Geisinger’s MyCode program. Among 175,500 people screened, 3.4%, roughly one in 30, carried a pathogenic variant in a potentially actionable gene. Nearly 90% of those people did not know about the risk before the result was disclosed.
For that minority, the finding can be extremely valuable. A BRCA1 or Lynch syndrome finding may lead to earlier cancer surveillance or preventive surgery. A familial hypercholesterolemia variant can change treatment and prompt testing of relatives. Certain heart-rhythm or cardiomyopathy variants can alter monitoring for an entire family.
Most of the genome is harder to use. Reports may contain carrier status, uncertain variants and polygenic risk scores that shift the estimated probability of common diseases without changing the recommended action. These scores also travel unevenly across ancestry groups because the training data have not represented every population equally well.
Interpretation changes over time, which is why current programs advertise annual reanalysis. That can be useful, though it also reveals how incomplete the first answer was.
We would pay for sequencing when family history, an unusual disease pattern or genetic counseling makes the result likely to guide care. Buying it simply to possess a complete digital copy of the genome is closer to informed curiosity than preventive medicine.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Does a biological age score tell you anything useful today?
A biological age score can describe risk patterns, but it cannot currently tell a customer how many years a clinic has added to or removed from their life.
Aging clocks use combinations of DNA methylation, proteins, metabolites, imaging or routine clinical measures. Some predict disease and mortality better than chronological age alone. A major Nature Medicine review published lately describes real future uses in risk detection, prevention and the study of anti-aging interventions.
Clinical use is still unsettled. Different clocks measure different parts of biology, so the same person can receive one age from an epigenetic test, another from blood proteins and several organ-specific ages from imaging. With no universal scale, treatment threshold or agreed definition of a meaningful change, before-and-after marketing is easy to overstate.
A score dropping from 54 to 49 after six months does not show that five years of aging were reversed. Laboratory variation, short-term inflammation, weight change or the model itself can move the result. Even a genuine biomarker improvement must still connect to fewer diseases or longer healthy life.
These tests interest researchers and motivate some customers. They may become much more useful as prospective studies link changes in clocks to clinical outcomes. Today, a clinic should present the result as an experimental risk estimate, never as a receipt proving rejuvenation.
Which longevity tests are actually worth paying for?
VO2 max, targeted bone-density testing, sleep studies and selected cardiovascular tests can be worth paying for because they measure known risks and lead to clear actions.
Cardiorespiratory fitness has one of the strongest cases. The American Heart Association has called it a clinical vital sign because low fitness is closely tied to cardiovascular and all-cause mortality. A measured VO2 max can expose poor fitness and guide training. A healthy recreational athlete may not need laboratory testing, but a sedentary client who uses the result to build a serious exercise plan could gain far more than from an aging clock.
DEXA is valuable when used for bone health in the right population. Current US guidance recommends osteoporosis screening for women aged 65 and older, and for younger postmenopausal women whose risk is elevated. Evidence remains insufficient for routine screening of all men. DEXA body-composition data can also guide resistance training, although small changes should not be treated as precise transformations.
Sleep testing earns its place when someone snores loudly, stops breathing during sleep, wakes unrefreshed, feels sleepy during the day or has risk factors such as obesity and resistant hypertension. Testing every symptom-free customer is harder to defend.
Cardiac testing should also follow risk. A coronary calcium scan can refine treatment decisions for some adults with uncertain cardiovascular risk. A CT coronary angiogram for every healthy buyer creates radiation, incidental findings and follow-up without the same evidence base.
The useful tests share a simple feature: we can name what the patient or clinician should do next.
| Test | Who is most likely to benefit | What a useful result changes |
|---|---|---|
| VO2 max or fitness assessment | Sedentary people, exercisers who need a baseline, people with unexplained exercise limitation | Training volume, intensity and medical evaluation |
| DEXA bone density | Women 65+, younger postmenopausal women at higher fracture risk, selected patients with risk factors | Fracture prevention, medication and strength training |
| Sleep study | People with symptoms or strong risk factors for sleep apnea | Treatment of apnea and related cardiovascular risk |
| Coronary calcium scan | Selected adults whose statin decision remains uncertain | Cardiovascular risk classification and preventive treatment |
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Should healthy people wear a glucose monitor?
Most healthy people do not need a continuous glucose monitor, and the latest review evidence still does not show that wearing one improves weight, long-term glucose control or health outcomes in people without diabetes.
CGMs are extremely valuable in diabetes. For everyone else, the device can reveal how meals, exercise, stress and sleep affect glucose over several days. Someone with prediabetes, metabolic syndrome or a strong family history may learn something useful from a short, structured trial.
The commercial pitch usually goes further. Normal rises after eating are often framed as dangerous “spikes,” even though the meaning of those brief changes in healthy people remains uncertain. Users may begin avoiding fruit, grains or other nutritious foods because an app scores one meal badly, while paying less attention to total diet quality, fitness, sleep and body weight.
A 2026 systematic review found that evidence for better glycemic measures, weight and behavior in non-diabetic populations remains unclear. Research is also moving quickly: a recent study analyzed CGM patterns in more than 8,000 adults without diagnosed diabetes and found that the data can reveal distinct metabolic profiles. Useful prediction, however, is different from proof that the consumer improves health by watching the graph.
We would treat a CGM as a short educational tool for a person with a specific metabolic question. Wearing one repeatedly for “optimization” has little proven value when HbA1c, fasting glucose, waist size, blood pressure and fitness already look healthy.
Are longevity IV drips, peptide stacks and supplements mostly hype?
Yes, much of the IV-drip and peptide side of longevity medicine currently rests on thin human evidence, loose quality control and claims that run far ahead of clinical trials.
Treating a documented deficiency is sensible medicine. Iron, vitamin B12 or another nutrient can be highly valuable when testing and symptoms show a real need. Giving high doses to someone who already has enough is unlikely to create extra longevity and can cause harm.
NAD+ infusions show how the wellness story can outrun the evidence. Clinics promote them for energy, cognition and cellular repair, yet controlled human evidence for broad anti-aging benefits remains weak. The FDA has received reports of severe chills, shaking, vomiting and fatigue after compounded injectable NAD+ products, with some patients needing medical treatment. Those reports were linked to concerns about ingredients unsuitable for sterile compounding.
Peptides have become even more popular lately. An FDA advisory panel has just recommended allowing pharmacies to compound several unapproved products, including BPC-157, TB-500 and MOTS-c. The vote may widen access, but it did not approve these substances as safe or effective drugs. FDA scientists had raised objections about limited human data and uncertain risks, and the agency has not made its final decision.
We would expect a clinic to show trials for the exact molecule, dose, route and patient group it treats. Testimonials about faster recovery or better energy do not answer those questions. When the evidence stops at animal studies, small uncontrolled reports or biological plausibility, the customer is funding an experiment.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Should healthy people take rapamycin, metformin or hormones for longevity?
Healthy people should not routinely take rapamycin, metformin, growth hormone or sex hormones for longevity today, because none has proved that use extends healthy human life in that population.
Rapamycin deserves serious research. It repeatedly extends lifespan in genetically varied mice, even when started later in life. Human trials, however, remain small and focus on short-term health measures. One of the largest recent studies enrolled 114 adults for 48 weeks and measured short-term health markers, not lifespan. Its results cannot establish that healthy users will live longer. Rapamycin can also affect immunity, lipids, blood cells, wound healing and glucose.
Metformin has decades of use in diabetes and an appealing safety record compared with many experimental drugs. Observational studies have linked it to better outcomes, but people prescribed metformin differ from comparison groups in ways that can distort the result. No randomized trial has shown that it extends life in healthy, non-diabetic adults.
Hormones require an actual medical diagnosis. Testosterone can help men with compatible symptoms and repeatedly confirmed low levels. Menopausal hormone therapy can be appropriate for selected women with symptoms after an individual risk discussion. Growth hormone can increase lean mass, while also causing edema, joint symptoms, carpal tunnel problems and impaired glucose control. The Endocrine Society says no growth-hormone treatment is approved as an anti-aging intervention.
Who has the best chance of getting real value from a longevity clinic?
People with neglected care, unusually high inherited risk or several poorly coordinated health problems have the best chance of getting real value from a longevity clinic.
Someone who has avoided doctors for years may arrive with untreated hypertension, diabetes, severe sleep apnea, dangerous cholesterol or overdue cancer screening. A thorough clinic can find those problems quickly and make sure the patient follows through.
When we see a strong family history, the calculation changes too. Several relatives with early breast, ovarian or colorectal cancer may justify genetic counseling and targeted surveillance. Premature heart attacks, sudden cardiac death or a known inherited condition can support deeper cardiovascular or genomic testing. In these cases, the clinic should build the work-up around the family pattern.
Another good candidate has connected risks that ordinary care has handled separately. Obesity, poor sleep, high blood pressure, fatty liver, low fitness and abnormal glucose often feed into one another. A clinician who coordinates treatment and keeps working with the patient may earn the premium.
Convenience also has value. A wealthy executive may reasonably pay to finish multiple appointments in one day and obtain rapid specialist access. That purchase is mostly premium service.
The weakest candidate is a healthy, low-risk adult who already has a careful primary care doctor, completes recommended screening and exercises consistently. Broad testing gives that person less room for benefit and plenty of room for incidental findings.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
At what price does a longevity clinic stop making sense?
Once a longevity package costs several thousand dollars, a healthy customer is usually paying more for access, convenience and exhaustive data than for a proven increase in healthy lifespan.
A low-cost laboratory membership can be reasonable when the buyer understands that broad panels create false alarms and has a clinician who will ignore meaningless noise. Around $1,000, we would expect real physician time, a complete preventive review and proper follow-up.
At several thousand dollars, each expensive test needs a personal reason. Family history, age, symptoms or an unresolved clinical decision can justify targeted imaging or genetics. “We include it for everyone” is a weak answer.
The $7,500 to $15,000 tier buys a luxury medical experience. Completing scans, blood tests, fitness testing and physician reviews in one place may be worth that amount to someone with very high income or very limited time. The expected medical benefit does not rise in proportion to the bill, because some of the costliest components still lack outcome evidence in healthy people.
A useful way to judge the invoice is to remove every scan and experimental test, then ask what remains. If the remaining product includes exceptional clinicians, coordination and sustained follow-up, there may be real value. If only a report and supplement list remain, the premium is difficult to defend.
| Price level | What we should expect | Our judgment for a healthy, average-risk adult |
|---|---|---|
| A few hundred dollars a year | Convenient targeted labs, interpretation and basic follow-up | Often reasonable, with disciplined interpretation |
| Around $1,000 to $3,000 | Substantial physician time, preventive review, fitness or risk-led testing and follow-up | Can be worthwhile when normal care is poor |
| Several thousand dollars | Individual reasons for advanced imaging, genetics or specialist coordination | Hard to justify as a fixed package |
| $7,500 to $15,000+ | Exceptional access, one-day convenience and year-round coordination | Mainly a luxury purchase unless personal risk is unusually high |
Are longevity clinics actually worth the money?
Mostly no: premium longevity clinics are not worth the money for healthy, average-risk adults, although a well-run clinic can be valuable when it fixes a real gap in someone’s care.
The strongest services are the least futuristic. Careful risk assessment, blood-pressure treatment, appropriate cholesterol management, evidence-based cancer screening, fitness improvement, sleep-apnea treatment and sustained follow-up can prevent disease. A clinic that delivers those unusually well may justify a meaningful premium.
The expensive additions have a weaker case. Whole-body MRI finds some serious disease but also produces many incidental findings, with no proof of better survival. Galleri has produced an encouraging reduction in stage IV diagnoses while missing its main randomized-trial endpoint. Genome screening changes care for a small minority. Biological age scores, CGMs for healthy users, NAD+ drips and peptide stacks remain much easier to sell than to validate.
In our view, the best clinic will sometimes recommend fewer tests than the customer expected. It will explain the chance of false alarms, separate established care from experiments, avoid broad anti-aging prescribing and stay involved after the results arrive. Those habits reveal more about quality than the number of biomarkers on the website.
For most healthy people, excellent primary care, the right screening, consistent exercise and targeted specialist advice will produce more dependable value at a fraction of the cost. Longevity clinics become worth paying for when they make that basic system work much better. Expensive measurements alone do not get them there.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
OUR METHODOLOGY
This analysis tests whether longevity clinics are worth the money for healthy customers by separating the product into preventive care, advanced screening, continuous clinical support, convenience and experimental anti-aging treatment. We did not treat those components as equally useful simply because they appear inside the same package.
For each component, we examined current clinic offerings and prices, randomized trials, systematic reviews, professional guidelines, large clinical datasets, regulatory decisions and recently reported trial results. We separated the ability to detect an abnormality from evidence that acting on it improves health.
We gave the greatest weight to outcomes that matter to patients: fewer heart attacks, strokes, advanced cancers, fractures, disabilities and deaths. Changes in biomarkers, imaging findings or biological age scores were treated as intermediate evidence unless they had a clear connection to better clinical outcomes.
We also considered harms and downstream burden. Broad testing can create false alarms, incidental findings, repeat imaging, biopsies, specialist visits and years of surveillance, so a test was not judged only by how often it found something.
Price was assessed against the part of the service that has established medical value. Lower-cost laboratory access, physician time and follow-up were judged differently from fixed packages containing whole-body MRI, multi-cancer blood testing, genome sequencing, continuous glucose monitoring, IV infusions, peptides or off-label drugs.
The final judgment reflects the balance between evidence, personal risk, quality of follow-up, convenience and price. A clinic can still provide real value without proving that its complete package extends lifespan, but the case becomes weaker as the offer shifts from targeted care toward exhaustive testing and experimental treatment.
Key sources used for this analysis include: Function Health on membership, testing and pricing, Human Longevity on programs, diagnostics and pricing, JAMA on general health checks in adult primary care, JAMA’s clinical evidence review of general health checks and mortality, the USPSTF recommendation on ECG screening in asymptomatic adults, the American College of Radiology statement on total-body MRI screening, the 2026 whole-body MRI systematic review and meta-analysis, GRAIL on the NHS-Galleri randomized-trial results, Nature Medicine on biological aging clocks, the American Heart Association on cardiorespiratory fitness as a clinical vital sign, the USPSTF recommendation on osteoporosis screening, the FDA warning concerning injectable compounded NAD+ products, and the FDA assessment of potentially high-risk substances used in compounding.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Which startup is ahead in longevity checkups?
- Who is emerging as the leader in preventive health?
